Speakers

Howard Federoff

Chief Medical Officer & Co-Founder

Kenai Therapeutics, FL

Kevin Beck

Head of Commercial Development,
Viral Vectors

MilliporeSigma, CA

Irene Rombel

President and CEO

BioCurie, DE

Jim McNally

Chief Scientific Officer

Sword Bio, MA

Rita Johnson-Greene

Chief Operating Officer

Alliance for Regenerative Medicine, PA

Vladimir Slepushkin

Chief Technology Officer

MedTherapy Biotech, MA

Priya Baraniak

Chief Commercial and Development Officer

Pluristyx, Inc., PA

Daniel J.Kota

Director, Office of Translational Production and Quality

Houston Methodist, TX

Chris Mason

Professor of Cell & Gene Therapy

University College of London, United Kingdom

Alessandra De Riva

Head of Process Development and R&D

Advent Bioservices, United Kingdom

Amir Hefni

Chief Executive Officer

Resolution Therapeutics, United Kingdom

Emmanuelle Cameau

Scientific Director - Viral vectors and other modalities

Cytiva, France

Jane Andrews

CEO & Founder

Cell Bridge Strategies, TX

Sally Gu

Senior Associate, Life Sciences/FDA

Hogan Lovells, DC

Yu Cao

VP, Global Head of Drug Discovery

GenEditBio Limited, MA

John Boyce

Managing Director and Co-Founder

TigerGene LLC, MA

John Zhao

Director Process Development

Kytopen, MA

Ohad Karnieli

Founder and CEO

ADVA Biotechnology, Israel

François Gianelli

Chief Regulatory and Quality Officer

TreeFrog Therapeutics, France

John Lu

President and CEO

Sanjeev Luther

President & CEO

Ernexa Therapeutics, MA

Cassandra Perkins

Vice President, Corporate Strategy & Business Development

Mercury Bio, Mexico

Larry Forman

Founder and CEO

CHO Plus, Inc., CA

Jonathan Rodriguez

QC Manager

Cedars-Sinai Biomanufacturing Center, LA

Elena Buglo

Consultant

The Genesis Project Foundation, FL

Xiaomo Wu

Principal investigator

Dermatology Hospital of Fuzhou, China

Sarah Dickerson

Director

KBI Biopharma, CO

Brian Furmanski

Chief Regulatory Officer

Kriya Therapeutics, NC

Rob Tressler

Chief Scientific Officer

Excellos, Inc., SF